Abstract
Despite nearly 30 years of development and recent highlights of nitric oxide (NO) donors and NO delivery systems in anticancer therapy, the limited understanding of exogenous NO’s effects on the immune system has prevented their advancement into clinical use. In particular, the effects of exogenously delivered NO differing from that of endogenous NO has obscured how the potential and functions of NO in anticancer therapy may be estimated and exploited despite the accumulating evidence of NO’s cancer therapy–potentiating effects on the immune system. After introducing their fundamentals and characteristics, this review discusses the current mechanistic understanding of NO donors and delivery systems in modulating the immunogenicity of cancer cells as well as the differentiation and functions of innate and adaptive immune cells. Lastly, the potential for the complex modulatory effects of NO with the immune system to be leveraged for therapeutic applications is discussed in the context of recent advancements in the implementation of NO delivery systems for anticancer immunotherapy applications.
SIGNIFICANCE STATEMENT Despite a 30-year history and recent highlights of nitric oxide (NO) donors and delivery systems as anticancer therapeutics, their clinical translation has been limited. Increasing evidence of the complex interactions between NO and the immune system has revealed both the potential and hurdles in their clinical translation. This review summarizes the effects of exogenous NO on cancer and immune cells in vitro and elaborates these effects in the context of recent reports exploiting NO delivery systems in vivo in cancer therapy applications.
Footnotes
- Received September 21, 2021.
- Revision received May 15, 2022.
- Accepted July 5, 2022.
This work was supported by National Institutes of Health National Cancer Institute [Grant R01-CA207619]. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.
- Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
In this issue
Jump to section
- Article
- Visual Overview
- Abstract
- I. Introduction
- II. NO-donors
- III. Design of NO Delivery Systems
- IV. Direct Effects of NO on the Immunogenicity of Cancer Cells In Vitro
- V. Direct Effects of NO on Immune Cells In Vitro
- VI. Recent Advances in Antitumor Immunotherapy Leveraging NO-Delivery Systems In Vivo
- VII. Conclusions and Perspective
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters